GR20180100090A - Pharmaceutical formula in the form of gel for patients with eosinophilic esophagitis - Google Patents
Pharmaceutical formula in the form of gel for patients with eosinophilic esophagitis Download PDFInfo
- Publication number
- GR20180100090A GR20180100090A GR20180100090A GR20180100090A GR20180100090A GR 20180100090 A GR20180100090 A GR 20180100090A GR 20180100090 A GR20180100090 A GR 20180100090A GR 20180100090 A GR20180100090 A GR 20180100090A GR 20180100090 A GR20180100090 A GR 20180100090A
- Authority
- GR
- Greece
- Prior art keywords
- gel
- budesonide
- eosinophilic esophagitis
- patients
- magaldrate
- Prior art date
Links
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 title claims abstract description 7
- 201000000708 eosinophilic esophagitis Diseases 0.000 title claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 8
- 229960004436 budesonide Drugs 0.000 claims abstract description 8
- NNGFFDRXGAELQA-UHFFFAOYSA-A pentaaluminum;decamagnesium;hentriacontahydroxide;disulfate Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O NNGFFDRXGAELQA-UHFFFAOYSA-A 0.000 claims abstract description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004544 cortisone Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 229960004018 magaldrate Drugs 0.000 claims description 2
- 230000009474 immediate action Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 5
- 206010030164 Oesophageal dilatation Diseases 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 description 6
- 239000006187 pill Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Abstract
Description
Φαρμακευτικό σκεύασμα σε μορφή γέλης για ασθενείς με Ηωσινοφυλική Οισοφαγίτιδα Medicinal preparation in gel form for patients with Eosinophilic Esophagitis
Η παρούσα εφεύρεση αφορά σε ένα νέο κορτιζονούχο φαρμακευτικό σκεύασμα σε μορφή καταπινόμενης γέλης (gel), το οποίο έχει ως κύρια συστατικά την βουδεσονίδη (Budesonide), συνθετικό, μη αλογονωμένο κορτικοστεροειδές, και την μαγαλδράτη (Magaldrate Anhydrous), αντιόξινη ουσία, η φαρμακολογική δράση της οποίας βασίζεται στην εξουδετέρωση του γαστρικού οξέος. Το σκεύασμα αυτό είναι χρήσιμο σε ασθενείς, οι οποίοι πάσχουν από Ηωσινοφυλική Οισοφαγίτιδα, καθώς με τη σωστή χορήγηση και δοσολογία βοηθά στην διάνοιξη των μεμβρανών του οισοφάγου, χωρίς να χρειάζεται περαιτέρω επεμβατική μέθοδος. The present invention concerns a new cortisone medicinal preparation in the form of a swallowable gel (gel), which has as its main ingredients Budesonide, a synthetic, non-halogenated corticosteroid, and Magaldrate Anhydrous, an antacid substance, the pharmacological action which is based on the neutralization of gastric acid. This preparation is useful for patients who suffer from Eosinophilic Esophagitis, as with the correct administration and dosage it helps to open the membranes of the esophagus, without the need for a further invasive method.
Φαρμακευτικά σκευάσματα για την θεραπεία της Ηωσινοφυλικής Οισοφαγίτιδας υπάρχουν μόνο σε μορφή χαπιού/ταμπλέτας. Ωστόσο, τα συγκεκριμένα σκευάσματα, επειδή δεν έχουν την μορφή της γέλης (gel) δεν δρουν απευθείας πάνω στις μεμβράνες του οισοφάγου, αλλά στο στομάχι, αποδεσμεύοντας σταδιακά την δραστική ουσία στον οργανισμό του ασθενούς. Pharmaceutical preparations for the treatment of Eosinophilic Esophagitis exist only in pill/tablet form. However, the specific preparations, because they do not have the form of a gel, do not act directly on the membranes of the esophagus, but on the stomach, gradually releasing the active substance in the patient's body.
Η παρούσα εφευρέτης, ως αποτέλεσμα εκτενούς έρευνας, βρήκε ένα φαρμακευτικό σκεύασμα, το οποίο έχοντας την μορφή της καταπινόμενης γέλης (gel), μπορεί να έχει πολύ πιο άμεσα αποτελέσματα και ταχύτατη δράση, συγκριτικά με τα αντίστοιχα υφιστάμενα φαρμακευτικά σκευάσματα σε μορφή χαπιού/ταμπλέτας. Συγκεκριμένα, το κορτιζονούχο σκεύασμα το οποίο πραγματεύεται η παρούσα εφεύρεση λαμβανόμενο εκ του στόματος επικάθεται στις μεμβράνες του οισοφάγου δημιουργώντας ένα λεπτό στρώμα, και ως εκ τούτου δρα απευθείας, τοπικά, πάνω στις μεμβράνες με αποτέλεσμα σε ταχύτατο χρόνο, ακόμα και μέσα σε χρονικό διάστημα θεραπείας τριών μηνών, να υφίσταται διάνοιξη του οισοφάγου και αποτελεσματική θεραπεία της νόσου. The present inventor, as a result of extensive research, found a pharmaceutical preparation, which, having the form of an ingestible gel (gel), can have much more immediate results and a very fast action, compared to the corresponding existing pharmaceutical preparations in pill/tablet form. In particular, the cortisone formulation that the present invention deals with when taken orally is deposited on the membranes of the esophagus creating a thin layer, and therefore acts directly, locally, on the membranes with a result in a very fast time, even within a period of treatment three months, to undergo opening of the esophagus and effective treatment of the disease.
Συγκεκριμένα, το παρόν περιγραφόμενο φαρμακευτικό σκεύασμα αποτελείται από 800 Mgr της ουσίας Μαγαλδράτης (Magaldrate Anhydrous) για κάθε 1 Mgr της ουσίας Βουδεσονίδης (Budesonide), η οποία μπορεί να χρησιμοποιηθεί είτε με την μορφή της σκόνης, είτε σε υγρή μορφή και με αυτήν την αναλογία λαμβάνεται εκ του στόματος στην μορφή της καταπινόμενης γέλης, ώστε ο συνδυασμός των δύο αυτών κύριων ουσιών να έχει άμεση επίδραση στις μεμβράνες του οισοφάγου και να καθιστά ταχύτερη και αμεσότερη την διάνοιξη του οισοφάγου. Specifically, the present described pharmaceutical preparation consists of 800 Mgr of the substance Magaldrate (Magaldrate Anhydrous) for every 1 Mgr of the substance Budesonide (Budesonide), which can be used either in the form of powder or in liquid form and with this ratio taken orally in the form of the swallowed gel, so that the combination of these two main substances has a direct effect on the membranes of the esophagus and makes the opening of the esophagus faster and more immediate.
Η περιγραφόμενη εφεύρεση αποτελεί αξιόπιστο φαρμακευτικό σκεύασμα και κατάλληλο για την θεραπεία της Ηωσινοφυλικής Οισοφαγίτιδας. The described invention is a reliable pharmaceutical preparation and suitable for the treatment of Eosinophilic Esophagitis.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20180100090A GR20180100090A (en) | 2018-03-06 | 2018-03-06 | Pharmaceutical formula in the form of gel for patients with eosinophilic esophagitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20180100090A GR20180100090A (en) | 2018-03-06 | 2018-03-06 | Pharmaceutical formula in the form of gel for patients with eosinophilic esophagitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR20180100090A true GR20180100090A (en) | 2019-10-16 |
Family
ID=68240881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20180100090A GR20180100090A (en) | 2018-03-06 | 2018-03-06 | Pharmaceutical formula in the form of gel for patients with eosinophilic esophagitis |
Country Status (1)
| Country | Link |
|---|---|
| GR (1) | GR20180100090A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116869927A (en) * | 2023-09-06 | 2023-10-13 | 中国医学科学院北京协和医院 | Esophageal thermosensitive gel for treating eosinophilic esophagitis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070111978A1 (en) * | 2005-11-12 | 2007-05-17 | Ranjan Dohil | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| WO2009132048A2 (en) * | 2008-04-21 | 2009-10-29 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| EP2211986A1 (en) * | 2007-10-16 | 2010-08-04 | Medtronic, Inc. | Therapy control based on a patient movement state |
-
2018
- 2018-03-06 GR GR20180100090A patent/GR20180100090A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070111978A1 (en) * | 2005-11-12 | 2007-05-17 | Ranjan Dohil | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| EP2211986A1 (en) * | 2007-10-16 | 2010-08-04 | Medtronic, Inc. | Therapy control based on a patient movement state |
| WO2009132048A2 (en) * | 2008-04-21 | 2009-10-29 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116869927A (en) * | 2023-09-06 | 2023-10-13 | 中国医学科学院北京协和医院 | Esophageal thermosensitive gel for treating eosinophilic esophagitis |
| CN116869927B (en) * | 2023-09-06 | 2023-11-10 | 中国医学科学院北京协和医院 | Esophageal thermosensitive gel for treating eosinophilic esophagitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Regnard et al. | A guide to symptom relief in palliative care | |
| Wesdorp et al. | Effect of long-term treatment with cimetidine and antacids in Barrett's oesophagus. | |
| CO4940409A1 (en) | COVERED TABLET WITH FILM FOR IMPROVED SAFETY OF THE UPPER GASTROINTESTINAL TRACT | |
| JP5970189B2 (en) | Pharmaceutical preparation | |
| KR20180033517A (en) | Mussel adhesive protein product, and its use for inhibiting mucosal inflammation | |
| SU1414392A1 (en) | Antiulcerous agent | |
| RU2025128C1 (en) | Agent for treatment of inflammatory diseases of esophagus and inflamatory and ulcer diseases of gastrointestinal tract | |
| GR20180100090A (en) | Pharmaceutical formula in the form of gel for patients with eosinophilic esophagitis | |
| RU2143906C1 (en) | Use of dimethicon for treatment of patients with aphthae and stomatitis | |
| Kajihara | Dabigatran-induced esophagitis | |
| Polonsky et al. | Familial achalasia | |
| DALY et al. | Acute corrosive esophagitis | |
| Segelnick et al. | Recognizing doxycycline-induced esophageal ulcers in dental practice: a case report and review | |
| US6319951B1 (en) | Use of 3-amino-4-hydroxybenzoic acid for the treatment of retroviral infections | |
| JP2016537425A (en) | Method of treating gastrointestinal injury caused by radiation | |
| Hire et al. | Paracetamol induced fixed drug eruption: A case report | |
| RU2628812C1 (en) | Method for conservative treatment of residual precancerous gastric diseases | |
| Miller et al. | Steroid treatment of lye burns of the esophagus | |
| RU2699567C1 (en) | Method of treating helicobacter pylori infection in adults | |
| RU2774597C1 (en) | Method for producing a medicinal product | |
| Hara | CVIII Stricture of the Esophagus following Pregnancy: A Case Report | |
| Yildar et al. | A phosphate enema-associated chemical colitis | |
| ES2452351T3 (en) | Use of phosphatidylcholine for the treatment of steroid-dependent ulcerative colitis and steroid refractory | |
| Elipek et al. | Oesophageal ulceration of a young female patient after doxycycline treatment | |
| RU2347566C1 (en) | METHOD FOR TREATMENT OF STOMACH AND DUODENUM DISEASES CAUSED BY Helicobacter pylori, MODIFIED BY SLOWDOWN OF MUCOUS MEMBRANE CLEARANCE FROM CHEMOTHERAPEUTICAL DRUGS WITH ANTICHOLINERGIC DRUG |